Introduction
Pancreatic ductal adenocarcinoma (PDAC) is a dismal disease characterized by poor prognosis, recurrence and resistance to chemotherapy [1,2]. PDAC is the second most frequent cancer of the gastrointestinal tract, the third principal cause of cancer overall
and the fourth major fatal illness in the United States. Curative surgery, defined as R0resection and adjuvant chemotherapy, is still currently the canonical regimen for patients with resectable, non-metastatic PDAC [3]. In advanced stages, when in the presence of local
or metastatic spread, a combination of gemcitabine and Nab-paclitaxel or mFOLFIRINOX is the usual treatment [4]. … (continua a leggere)